Jim Cramer answered viewers' Twitter from the floor of the New York Stock Exchange, commenting on Qorvo (QRVO), Celgene (CELG), Boston Scientific (BSX), and on why September is a tough month on Wall Street. A viewer asked about Qorvo. Cramer said the company had a disappointing quarter, which brought down other stocks including NXP Semiconductors (NXPI), which he likes better, and Skyworks Solutions (SWKS), which he says to buy in the 70s. Another viewer asked about a good entry point for Celgene (CELG), which Cramer said is a buy at $113 or below. Cramer was asked about his views on Boston Scientific (BSX), which he said is a good company, and that he likes the whole group, including CR Bard (BCR), Medtronic (MDT), Edwards Life Sciences (EW), and St. Jude Medical (STJ). Send your Twitter questions to @JimCramer using #CramerQ.
More from Video
Amid the Selling, Here's the Big Question Now
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
One Tweet Pulls the Rug Out From Under the Indexes
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
A Technical Look at the New Dow Jones Industrial Average
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
Conagra Brands Looks Tastier After Its Upgrade to Buy
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts
Breaking down an approach to the long side of this biotech stock.
Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation.
If you have questions, please contact us here.